Linked Life Data

17354661

Source:http://linkedlifedata.com/resource/pubmed/id/17354661

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
93
pubmed:dateCreated
2007-3-14
pubmed:abstractText
The 2006 vintage leads to decreased enthusiasm in medical oncology, compared to the amazing 2005. One notable exception is the marketing of sunitinib and sorafenib, two agents which increase remarkably the chances of benefiting renal cell cancer patients. Several of the reviewed papers indicate the need to better target cancer treatment, including chemotherapy. One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1660-9379
pubmed:author
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
49-52, 54-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Medical oncology].
pubmed:affiliation
Clinique de Genolier, 1272 Genolier. maapro@genolier.net
pubmed:publicationType
Journal Article, English Abstract, Review